News
Public · Published
Morgan Stanley maintains Denali Therapeutics at Overweight, raises price target to $42 from $40
Morgan Stanley kept its Overweight rating on Denali Therapeutics and raised its price target to $42 from $40. The new target is 5.0% higher and implies 115.9% upside from Denali's Nov. 3 closing price of $19.45.
Published:
Updated:
What happened
Morgan Stanley kept its Overweight rating on Denali Therapeutics and raised its price target to $42 from $40. The new target is 5.0% higher and implies 115.9% upside from Denali’s Nov. 3 closing price of $19.45.
Confirmed
Global impact / market context
The higher target signals that Morgan Stanley sees greater potential value in Denali than before, while the unchanged Overweight rating shows its stance did not change. If investors respond by buying shares, that demand could support the stock price, but the target is an analyst estimate, not a promised return.
Analyst inference
The article gives one analyst’s revised target and compares it with a past closing price; it does not report Denali’s current share price, company results, or other analysts’ views. The stated upside is therefore a comparison, not evidence that the shares will rise by that amount.
Analyst inference
What to watch
- Check Denali’s later share price against the $19.45 Nov. 3 close cited in the article; the target’s stated upside depends on that reference price. Analyst inference
- Watch for future Morgan Stanley rating or target changes, which would show whether the analyst maintains or revises this view of Denali. Analyst inference
- Compare any later company results or business updates with the outlook implied by the higher target, while noting that the article provides no operating forecasts. Analyst inference
Evidence
- Original source link unavailable